Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, and existing screening approaches—such as blood tests and transvaginal ultrasound—can miss the disease at stages when treatment is most effective. In recent years, research has reshaped understanding of how many aggressive ovarian cancers begin, pointing not to the ovary itself, but to the fallopian tubes. That shift has created a need for tools that can safely examine these narrow structures for early changes linked to cancer.
This article was originally published on MedicalXpress.com
